Worldwide IP coverage of patented inventions in large pharma firms: to what extent do the internationalisation of R&D and firm strategy matter?

The paper deals with the determinants of worldwide IP coverage of patented inventions in large pharmaceutical firms. We support the core idea that the internationalisation of firm R&D and an economic presence in a foreign country are positive key factors which explains global IP coverage. For the global pharmaceutical industry, we estimate probit models on the probability that a patent will be expanded worldwide. We retain two categories of worldwide patent: the well-known triadic patent and the new triadic one (triadic + China + Korea). The data set encompasses the 17,633 priority patents applied for by 76 enterprises from several countries over the period 2003-2005. One important finding is that patenting in Japan sets up an important barrier, giving Japanese firms an advantage when triadic patenting is considered. For European and US firms, our estimation results confirm the idea that the level of firm R&D internationalisation is a significant explanatory factor in international IP coverage, together with control variables. We highlight an inverted U-shaped relationship between these two variables. The hypothesis related to a firm economic presence is also verified.

[1]  Lee Branstetter,et al.  Is Foreign Direct Investment a Channel of Knowledge Spillovers? Evidence from Japan&Apos;S FDI in the United States , 2000 .

[2]  Philippe Larédo,et al.  The artificial patents in the PATSTAT database: How much do they matter when computing indicators of internationalisation based on worldwide priority patents? , 2017, Scientometrics.

[3]  R. Griffith,et al.  The location of innovative activity in Europe , 2008 .

[4]  M. Miozzo,et al.  Big Pharma's Internationalization of R&D to China , 2015 .

[5]  Paul Almeida,et al.  Knowledge sourcing by foreign multinationals: Patent citation analysis in the U.S. semiconductor industry , 1996 .

[6]  Christian Sternitzke,et al.  Defining triadic patent families as a measure of technological strength , 2009, Scientometrics.

[7]  K. Bjorvatn,et al.  Technology Sourcing and Strategic Foreign Direct Investment , 2006 .

[8]  E. Roberts.  Benchmarking Global Strategic Management of Technology , 2001 .

[9]  H. Grupp,et al.  Patent statistics in the age of globalisation: new legal procedures, new analytical methods, new economic interpretation , 1999 .

[10]  Bruno van Pottelsberghe de la Potterie,et al.  A Policy Insight into the R&D-Patent Relationship , 2007 .

[11]  M. Vivarelli,et al.  Drivers and Impacts in the Globalization of Corporate R&D: An Introduction Based on the European Experience , 2011, SSRN Electronic Journal.

[12]  I. Cockburn,et al.  Patents and the Global Diffusion of New Drugs , 2014, The American economic review.

[13]  Ming Liu,et al.  A cross-country index of intellectual property rights in pharmaceutical inventions , 2015 .

[14]  Marcus M. Keupp,et al.  How do foreign firms patent in emerging economies with weak appropriability regimes? Archetypes and motives , 2012 .

[15]  G. Dosi,et al.  Knowledge accumulation and industry evolution: the case of Pharma-Biotech , 2006 .

[16]  K. Pavitt,et al.  Large Firms in the Production of the World's Technology: An Important Case of “Non-Globalisation” , 1991 .

[17]  W Kuemmerle,et al.  Building effective R&D capabilities abroad. , 1997, Harvard business review.

[18]  L. Piscitello.  Strategy, location, and the conceptual metamorphosis of the MNE , 2011 .

[19]  R. Narula,et al.  The investment development path in a globalised world: implications for Eastern Europe , 2010 .

[20]  J. Cantwell.  The Globalisation of Technology: What Remains of the Product Cycle Model? , 1995 .

[21]  W. Kuemmerle.  The Drivers of Foreign Direct Investment into Research and Development: An Empirical Investigation , 1999 .

[22]  Keith E. Maskus,et al.  Intellectual property rights in the global economy , 2000 .

[23]  Daniele Archibugi,et al.  Technology, globalisation and economic performance , 1997 .

[24]  Brent B. Allred,et al.  Patent rights and innovative activity: evidence from national and firm-level data , 2007 .

[25]  Nadine Roijakkers,et al.  Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns, and networks , 2006 .

[26]  The Management of Intellectual Property: Introduction , 2006 .

[27]  Shubham Chaudhuri,et al.  Estimating the E ff ects of Global Patent Protection for Pharmaceuticals : A Case Study of Fluoroquinolones in India ∗ , 2003 .

[28]  Stephen Tallman.  Managing across Borders: The Transnational Solution , 1990 .

[29]  M. Jakovljevic.  The Key Role of the Leading Emerging Bric Markets in the Future of Global Health Care , 2014 .

[30]  A. Rugman,et al.  Inside The Multinationals , 1981 .

[31]  J. Vang.  Multinationals and Economic Geography: Location, Technology and Innovation , 2014 .

[32]  Hélène Dernis,et al.  Triadic Patent Families Methodology , 2004 .

[33]  Rainer Frietsch,et al.  Patent families as macro level patent value indicators: applying weights to account for market differences , 2012, Scientometrics.

[34]  Hiroyuki Odagiri,et al.  Overseas R&D, knowledge sourcing, and patenting: an empirical study of Japanese R&D investment in the US , 2004 .

[35]  Sanjaya Lall,et al.  The International Allocation of Research Activity by US Multinationals , 1979 .

[36]  O. Gassmann,et al.  Market versus technology drive in R&D internationalization: four different patterns of managing research and development , 2002 .

[37]  Peter Gammeltoft,et al.  Internationalisation of R&D: trends, drivers and managerial challenges , 2006 .

[38]  Bruno van Pottelsberghe de la Potterie,et al.  The Worldwide Count of Priority Patents: A New Indicator of Inventive Activity , 2012 .

[39]  P. Larédo,et al.  Internationalisation of European MNCs R&D: “deglobalisation” and evolution of the locational strategies , 2018 .

[40]  F. Malerba,et al.  The evolution of the pharmaceutical industry , 2015 .

[41]  Rajneesh Narula,et al.  Globalisation of Innovation : The Role of Multinational Enterprises , 2003 .

[42]  F. Pammolli,et al.  Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure. , 2007, The European journal of health economics : HEPAC : health economics in prevention and care.

[43]  Albert G Z Hu.  Propensity to Patent, Competition and China's Foreign Patenting Surge , 2008 .

[44]  C. L. Bas,et al.  'Location versus home country advantages' in R&D activities: some further results on multinationals' locational strategies , 2002 .

[45]  Robert Ronstadt,et al.  International R&D: The Establishment and Evolution of Research and Development Abroad by Seven U.S. Multinationals , 1978 .

[46]  Hiroyuki Odagiri,et al.  The determinants of overseas R&D by Japanese firms: an empirical study at the industry and company levels , 1996 .

[47]  J. Mahlich.  Patents and performance in the Japanese pharmaceutical industry: An institution-based view , 2010 .

[48]  Sarianna M. Lundan,et al.  The Internationalization of Corporate R&D: A Review of the Evidence and Some Policy Implications for Home Countries , 2008 .

[49]  Yun-chung Chen,et al.  Why Do Multinational Corporations Locate Their Advanced R&D Centres in Beijing? , 2008 .

[50]  H. Chan.  The Determinants of International Patenting for Nine Agricultural Biotechnology Firms , 2010 .

[51]  John Cantwell,et al.  Multinational Corporations and the Location of Technological Innovation in the UK Regions , 2000 .

[52]  Oliver Gassmann,et al.  Leading Pharmaceutical Innovation: How to Win the Life Science Race , 2018 .

[53]  Fr¬¥ed¬¥erique Sachwald,et al.  Location choices within global innovation networks: the case of Europe , 2008 .

[54]  Massimo Riccaboni,et al.  Innovation and corporate growth in the evolution of the drug industry , 2001 .

[55]  P. Patel,et al.  Patterns of internationalisation of corporate technology: location vs. home country advantages. , 1999 .

[56]  Philippe Larédo,et al.  The rate and motives of the internationalisation of large firm R&D (1994–2005): Towards a turning point? , 2015 .

[57]  Björn Ambos.  Foreign direct investment in industrial research and development: A study of German MNCs , 2005 .

[58]  Kamal Saggi,et al.  Trade , Foreign Direct Investment , and International Technology Transfer : A Survey * , 2000 .

[59]  Walter G. Park,et al.  International patent protection: 1960-2005 , 2008 .

[60]  Jean O. Lanjouw,et al.  How to Count Patents and Value Intellectual Property: Uses of Patent Renewal and Application Data , 1996 .

[61]  Ryuhei Wakasugi,et al.  The effects of stronger intellectual property rights on technology transfer: evidence from Japanese firm-level data , 2009 .

[62]  William W. Fisher,et al.  Strategic Management of Intellectual Property: An Integrated Approach , 2013 .

[63]  Tony S. Frost.  The geographic sources of foreign subsidiaries' innovations , 2001 .